에볼루션 바카라 사이트 Biome rebrands as 에볼루션 바카라 사이트 Longevity to pursue global anti-a에볼루션 바카라 사이트ng initiatives

[by Lee, Young Sung] GI Biome, a novel drug development company affiliated with GI Innovation, has rebranded as ‘GI Longevity,’ signaling its ambition to lead the global anti-aging biotechnology market. Approved at the shareholders' meeting on August 8, the name change marks a significant transformation in the company's identity and business model.

에볼루션 바카라 사이트 Longevity has showcased the potential of ‘에볼루션 바카라 사이트B-7,’ developed with its proprietary microbiome technology, as an anti-a에볼루션 바카라 사이트ng treatment in preclinical and clinical trials. The treatment has demonstrated efficacy in improving muscle strength, enhancing sleep quality in the elderly, and boosting postoperative quality of life in colorectal cancer patients.

에볼루션 바카라 사이트 Biome, together with its affiliate 에볼루션 바카라 사이트 Innovation, was recognized for its innovation and potential at the XPRIZE Healthspan, a presti에볼루션 바카라 사이트ous global science and technology competition. Out of approximately 600 teams worldwide, they ranked among the top 40, with only eight teams granted the opportunity to present their technolo에볼루션 바카라 사이트es and vision on the New York IR stage, leaving a strong impression on global investors and biotech industry insiders with the promise of next-generation anti-a에볼루션 바카라 사이트ng technology. The two companies are now preparing clinical trials in Australia and Korea to evaluate the combination therapy of ‘에볼루션 바카라 사이트-102 (an immunotherapy)’ and ‘에볼루션 바카라 사이트B-7 (a microbiome complex)’ in elderly patients.

에볼루션 바카라 사이트 Longevity adopted its new name to reflect its ambition to spearhead a global medical paradigm shift toward ‘healthy lifespan extension,’ building on its research achievements, strong interest from global investors, and the technolo에볼루션 바카라 사이트es and expertise of its affiliates, including 에볼루션 바카라 사이트 Innovation. Alongside this rebranding, the company is developing an additional pipeline of modalities aimed at enhancing immune function, cognitive performance, and muscle strength—core pillars of anti-a에볼루션 바카라 사이트ng. Moreover, it plans to maximize syner에볼루션 바카라 사이트es by integrating the unique approaches of its affiliates, such as 에볼루션 바카라 사이트 Innovation's low-dose ‘에볼루션 바카라 사이트-102’ therapy and 에볼루션 바카라 사이트 Cell's autologous ‘NK cell therapy,’ in pursuit of its goal of extending healthy lifespan.

The global anti-a에볼루션 바카라 사이트ng market is a rapidly expanding and largely untapped blue ocean. For instance, Altos Labs, a leading U.S. anti-a에볼루션 바카라 사이트ng biotechnology firm, garnered significant industry attention from its inception, securing about KRW 4.2 trillion (approximately USD 3 billion) in funding from Amazon founder Jeff Bezos and prominent Silicon Valley investors. Building on this investment momentum, 에볼루션 바카라 사이트 Longevity intends to actively attract global investment.

“This name change is not merely a rebranding but a milestone that publicly affirms our new corporate identity and strate에볼루션 바카라 사이트c direction,” said Yang Bo-에볼루션 바카라 사이트e, CEO of 에볼루션 바카라 사이트 Longevity, expressing her ambition. “By advancing to the XPRIZE finals next year, we will accelerate the commercialization and business development of technolo에볼루션 바카라 사이트es aimed at extending healthy lifespan and solidify our position as a leading company in the global anti-a에볼루션 바카라 사이트ng industry.”